Who is sponsoring NCT04825652?

NCT04825652 is sponsored by Advanced Accelerator Applications.

What drugs are being tested in NCT04825652?

Interventions in NCT04825652: 177Lu-PSMA-617, PSMA-11.

What condition does NCT04825652 study?

NCT04825652 studies Metastatic Castration-resistant Prostate Cancer (mCRPC).

Is NCT04825652 still recruiting?

NCT04825652 is currently no longer available. Last updated 13 January 2023.

Last reviewed 2023-01-13 · How we verify

NCT04825652

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

NO LONGER AVAILABLE Last updated 13 January 2023

What this trial tests

trial testing 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (mCRPC). No longer available.

Quick facts

Lead sponsor	Advanced Accelerator Applications
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS

Drugs / interventions tested

177Lu-PSMA-617 — full drug profile →
PSMA-11 — full drug profile →

Conditions studied

Metastatic Castration-resistant Prostate Cancer (mCRPC) — all drugs for Metastatic Castration-resistant Prostate Cancer (mCRPC) →

Sponsor

Advanced Accelerator Applications — full company profile →

Who can join

18 and older, male only, with Metastatic Castration-resistant Prostate Cancer (mCRPC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this Cohort Treatment Plan is to allow access to 177Lu-PSMA-617 for eligible patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). The patient's treating physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, et al · · 2024 · cited 8× · PMID 39327018 · DOI 10.2967/jnumed.124.267816
PSMA PET/CT-Derived Indicators and Outcomes After [177Lu]Lu-PSMA-617: A Multicenter Retrospective Analysis from the U.S. Expanded-Access Program.
Kimura K, Murthy V, Voter AF, Solnes LB, et al · · 2026 · PMID 41679922 · DOI 10.2967/jnumed.125.270789
Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study.
Murthy V, Kimura K, Theus L, Nguyen A, et al · · 2026 · PMID 41344853 · DOI 10.2967/jnumed.125.270916

Verify or expand the search:

Other trials of 177Lu-PSMA-617

Trials testing the same drug.

NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
NCT06783348 — Radiopharmaceutical Treatment of Advanced Kidney Cancer · Phase 2 · not yet recruiting
NCT07025512 — 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia · Phase 2 · suspended
NCT06964958 — 177LuPSMA in Renal Cell Carcinoma · Phase 2 · active not recruiting
NCT06461689 — Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant · completed

Other recruiting trials for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Currently open trials in the same condition.

NCT06136650 — A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist · Phase 3 · recruiting
NCT05107674 — A Study of NX-1607 in Adults With Advanced Malignancies · Phase 1 · recruiting

Other Advanced Accelerator Applications trials

Trials by the same sponsor.

NCT04711135 — Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs · Phase 2 · active not recruiting
NCT04524442 — Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patie · Phase 4 · completed
NCT03972488 — Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET · Phase 3 · active not recruiting
NCT03872778 — [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake · Phase 1, PHASE2 · completed
NCT03691064 — Post-Authorization Long-Term Safety Study of LUTATHERA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04825652 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Advanced Accelerator Applications
Last refreshed: 13 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04825652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing